title: Discovery of purinergic signalling, the initial resistance and current explosion of interest.
abstract: There has been a remarkable growth of papers published about purinergic signalling via ATP since 1972. I am most grateful to the wonderful PhD students and postdoctoral fellows who have worked with me over the years to pursue the purinergic hypothesis despite early opposition and to the many outstanding scientists around the world who are currently extending the story. Recently, therapeutic approaches to pathological disorders include the development of selective P1 and P2 receptor subtype agonists and antagonists, as well as of inhibitors of extracellular ATP breakdown and of ATP transport enhancers and inhibitors. Medicinal chemists are starting to develop small molecule purinergic drugs that are orally bioavailable and stable in vivo.
authors.affiliation: Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London, UK. g.burnstock@ucl.ac.uk
authors.forename: G
authors.initials: G
authors.lastname: Burnstock
mesh_terms: D000255:Adenosine Triphosphate / Q000502:physiology*; D000818:Animals; D002450:Cell Communication / Q000502:physiology*; D007473:Ion Channels / Q000737:chemistry / Q000378:metabolism; D008958:Models, Molecular; D009130:Muscle, Smooth / Q000502:physiology; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000494:pharmacology; D011487:Protein Conformation; D011983:Receptors, Purinergic / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D012106:Research / Q000639:trends*; D015398:Signal Transduction / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology
chemical_list: D007473:Ion Channels; D018377:Neurotransmitter Agents; D011983:Receptors, Purinergic; D000255:Adenosine Triphosphate